VASCULAR ENDOTHELIAL GROWTH FACTOR VEGF-A AS A MARKER OF ENDOTHELIAL DYSFUNCTION ASSOCIATED WITH SEVERE COVID-19 IN PATIENTS WITH CHRONIC CONCOMITANT PATHOLOGY
Keywords:
Covid 19, comorbidity, vascular endothelial growth factor (VEGF A), endothelial dysfunction.Abstract
This study addresses the significance of vascular endothelial growth factor A (VEGF-A) as a potential biomarker of endothelial dysfunction in individuals with severe manifestations of COVID-19, particularly those with pre-existing chronic comorbidities such as diabetes mellitus, hypertension, obesity, and cardiovascular diseases. Endothelial dysfunction has emerged as a key pathological feature in severe SARS-CoV-2 infection, contributing to a range of complications including microthrombosis, exaggerated vascular permeability, and systemic inflammatory responses.The assessment of circulating VEGF-A levels in COVID-19 patients may serve as an early indicator of disease severity and endothelial injury, offering potential utility in risk stratification, prognosis, and therapeutic decision-making. Moreover, VEGF-A could be explored as a target for adjunctive therapy, aiming to mitigate endothelial dysfunction and its clinical consequences in high-risk patient populations.
References
Podzolkov, VI, Bragina, AE, Tarzimanova, AI, Vasilyeva, LV, Batrakova, EV, Lobova, NV, ... & Khachuroeva, MM (2021). Post-Covid syndrome and tachycardia: theoretical foundations and treatment experience. Rational pharmacotherapy in cardiology, 17(2), 256-262.(in Russian).
Svetozarsky, N. L., Artifexova, A. A., & Svetozarsky, S. N. (2015). Vascular endothelial growth factor: biological properties and practical significance (literature review). Journal of Siberian Medical Sciences, (5), 24.(in Russian).
Talotta, R. (2022). Impaired VEGF-A-mediated neurovascular crosstalk induced by SARS-CoV-2 spike protein: a potential hypothesis explaining long COVID-19 symptoms and COVID-19 vaccine side effects?. Microorganisms, 10(12), 2452.(in Russian).
Nekaeva, ES, Bolshakova, AE, Malysheva, ES, Galova, EA, Makarova, EV, Nekrasova, TA, ... & Fomin, IV (2021). Gender features of the course of the new coronavirus infection COVID-19 in mature individuals. Modern technologies in medicine, 13(4), 16-26. (in Russ).
Zaitsev, A. A., Savushkina, O. I., Chernyak, A. V., Kulagina, I. Ts., & Kryukov, E. V. (2020). Clinical and functional characteristics of patients who had the new coronavirus infection COVID-19. Practical Pulmonology, (1), 78-81. (in Russ).
Garg S. et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 States, March 1–30, 2020 //Morbidity and mortality weekly report. – 2020. – T. 69. – No. 15. – P. 458. (in Russ).
Datta, S. D., Talwar, A., & Lee, J. T. (2020). A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications. Jama, 324(22), 2251-2252. (in Russ).
Grigorenko, E., Ruzanov, D., & Statkevich, T. (2020). Coronavirus infection COVID-19 and comorbidity. Science and Innovation, (7 (209)), 50-60. (in Russ).
Kokaeva, IO, Zhernakova, Yu. V., & Blinova, N. B. (2022). Endothelial dysfunction in patients with COVID-19 is a key mechanism for the development of complications. Systemic hypertension, 19(4), 37-44. (in Russ).
Barbarash, O. L., Karetnikova, V. N., Kashtalap, V. V., Zvereva, T. N., & Kochergina, A. M. (2020). Novel coronavirus disease (COVID-19) and cardiovascular diseases. Complex Issues of Cardiovascular Diseases, 9(2), 17-28.(in Russian).
